![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
M Raiteri, R Leardi and M Marchi
The existence of multiple muscarinic receptors in the brain was investigated by using neurotransmitter release as a functional parameter and by comparing the effects of agonists and antagonists on three systems of release regulation mediated by presynaptic muscarinic receptors. The receptors selected as models for our experiments were: 1) the muscarinic autoreceptors mediating inhibition of acetylcholine release in the cortex; 2) the muscarinic autoreceptors present in the nerve endings of the hippocampus; and 3) the muscarinic presynaptic receptors mediating potentiation of striatal dopamine release (heteroreceptors). The experiments were performed by using rat brain synaptosomes in superfusion. Acetylcholine, oxotremorine and carbachol inhibited the release of [3H]acetylcholine evoked by 15 mM KCI in cortex and hippocampus and potentiated the K+-evoked [3H]dopamine release in the striatum. The concentration-response curves were similar in the three systems, the rank of potency being: acetylcholine greater than oxotremorine greater than carbachol. The effects of acetylcholine were counteracted by several muscarinic antagonists with different rank of potencies and different potency ratios. In particular, the rank of potencies for the drugs tested was: atropine greater than secoverine greater than stercuronium greater than pirenzepine at the autoreceptors, both in cortex and hippocampus; but it was: atropine greater than pirenzepine = secoverine greater than stercuronium, at the heteroreceptors in the striatum. Pirenzepine was 100 times more potent on heteroreceptors than on autoreceptors. Our results suggest the possibility of a differential activation or blockade of central muscarinic receptors by selective drugs.
This article has been cited by other articles:
|
|
 |
|
  T. J. Volz, S. J. Farnsworth, S. D. Rowley, G. R. Hanson, and A. E. Fleckenstein Methylphenidate-Induced Increases in Vesicular Dopamine Sequestration and Dopamine Release in the Striatum: The Role of Muscarinic and Dopamine D2 Receptors J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 161 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Gray and B. L. Roth Molecular Targets for Treating Cognitive Dysfunction in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1100 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Zhang, M. Yamada, J. Gomeza, A. S. Basile, and J. Wess Multiple Muscarinic Acetylcholine Receptor Subtypes Modulate Striatal Dopamine Release, as Studied with M1-M5 Muscarinic Receptor Knock-Out Mice J. Neurosci., August 1, 2002; 22(15): 6347 - 6352. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Abou-Donia, A. M. Dechkovskaia, L. B. Goldstein, S. L. Bullman, and W. A. Khan Sensorimotor Deficit and Cholinergic Changes following Coexposure with Pyridostigmine Bromide and Sarin in Rats Toxicol. Sci., March 1, 2002; 66(1): 148 - 158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamada, K. G. Lamping, A. Duttaroy, W. Zhang, Y. Cui, F. P. Bymaster, D. L. McKinzie, C. C. Felder, C.-X. Deng, F. M. Faraci, et al. Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice PNAS, November 9, 2001; (2001) 251542998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Auld, F. Mennicken, and R. Quirion Nerve Growth Factor Rapidly Induces Prolonged Acetylcholine Release from Cultured Basal Forebrain Neurons: Differentiation between Neuromodulatory and Neurotrophic Influences J. Neurosci., May 15, 2001; 21(10): 3375 - 3382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Khan, A. M. Dechkovskaia, E. A. Herrick, K. H. Jones, and M. B. Abou-Donia Acute Sarin Exposure Causes Differential Regulation of Choline Acetyltransferase, Acetylcholinesterase, and Acetylcholine Receptors in the Central Nervous System of the Rat Toxicol. Sci., September 1, 2000; 57(1): 112 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Auld, J. C. Day, F. Mennicken, and R. Quirion Pharmacological Characterization of Endogenous Acetylcholine Release from Primary Septal Cultures J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 692 - 697. [Abstract] [Full Text]
|
|
|
|
|
|
A. I. Levey Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease PNAS, November 26, 1996; 93(24): 13541 - 13546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mash, D. Flynn, and L. Potter Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation Science, May 31, 1985; 228(4703): 1115 - 1117. [Abstract] [PDF]
|
|
|
|
|
|
M. Yamada, K. G. Lamping, A. Duttaroy, W. Zhang, Y. Cui, F. P. Bymaster, D. L. McKinzie, C. C. Felder, C.-X. Deng, F. M. Faraci, et al. Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice PNAS, November 20, 2001; 98(24): 14096 - 14101. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
